Trial · SURPASS-CVOT

Tirzepatide cardiovascular outcomes (SURPASS-CVOT)

Active-comparator CV outcomes trial of tirzepatide vs dulaglutide in 13,299 adults with T2D and established CVD or high CV risk. Headline non-inferiority was met; superiority signals are being analyzed by indication subgroup.

Design

Multicenter, double-blind, double-dummy, active-comparator trial in adults with T2D and either established atherosclerotic CVD or multiple CV risk factors. Median follow-up approximately 5 years.

Implications

Strengthens the cardiometabolic positioning of tirzepatide as a foundational therapy alongside semaglutide, and informs payer coverage decisions for the higher-priced agent.